...
首页> 外文期刊>Nanomedicine research journal. >An appraisal of antifungal impacts of nano-liposome containing voriconazole on voriconazole-resistant Aspergillus flavus isolates as a groundbreaking drug delivery system
【24h】

An appraisal of antifungal impacts of nano-liposome containing voriconazole on voriconazole-resistant Aspergillus flavus isolates as a groundbreaking drug delivery system

机译:含伏立康唑对伏立康唑抗性曲霉属植物病蝇的抗真菌菌抗真菌菌的评估为突破性药物递送系统

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background: This study is an attempt to investigate the effect of nano-liposome containing voriconazole on voriconazole-resistant A. flavus strains on the one hand, and to consider the expression of cyp51A and MDR1genes, regarded as important genes involved in the development of resistance to triazoles before and after voriconazole and voriconazole-loaded nano-liposomes exert their effects, on the other hand.Methods: Strains of A. flavus isolated from patients were investigated and their susceptibility to voriconazole was determined. Next, having applied a slight modification to the thin film hydration-sonication technique, the liposomal formulation of voriconazole was produced. After that, the voriconazole-loaded nano-liposome was subjected to in-vitro antifungal susceptibility testing to obtain minimum inhibitory concentration against fungal isolates. Cyp51A and MDR1 mRNA levels were amplified by qRT-PCR instrument.Results: The effect of nano-liposome containing voriconazole on the reduction of MIC in A. flavus isolates were considered to be significant. After using MIC50 concentration of VCZ, the cyp51A gene expression in voriconazole-susceptible A. flavus strains and voriconazole-resistant strains 10folds and 7folds depicted a downregulation, respectively, which was more pronounced in the expression of a liposomal formulation of VCZ (13folds and 15folds respectively). Identically, the same procedure was applied to MDR1, even though it induced 1, 2, 3, 4-fold reductions.Conclusion: Considering the benefits of liposome-containing voriconazole formulation, such as the reduction of the side effects of the pure drug as well as minimizing the drug's toxicity coupled with the enhanced drug bioavailability and stability, the formulation can be used in drug-sensitive and drug-resistant species.
机译:背景:本研究试图探讨含有voriconazole对伏立康唑抗性A.的含有voricoNazole的含量的影响,并考虑CYP51a和MDR1Genes的表达,被认为是患有抗性发展的重要基因另外,在伏立康唑和伏立康唑和纳米脂质体之前和之后的三唑施用它们的效果。方法:研究了从患者分离的患者分离的黄色菌株,测定它们对伏立康唑的敏感性。接下来,对薄膜水合超声技术进行轻微改性,制备了伏立康唑的脂质体制物。之后,进行伏荷达唑负载的纳米脂质体,进行体外抗真菌敏感性测试,以获得对真菌分离株的最小抑制浓度。通过QRT-PCR仪表扩增CYP51A和MDR1 mRNA水平。结果:纳米脂质体含有伏立康唑对A.FlaVus分离物中MIC的减少的影响是显着的。在使用VCZ的MIC50浓度之后,voriconazole易感A.的CYP51A基因表达分别为vorvus菌株和抗血酮抗性菌株10倍和7个,其分别描绘了下调的下调,其在表达VCZ的脂质体制物(13倍和15倍)中更为显着。分别)。相同地,施加相同的程序对MDR1,即使它诱导1,2,3,4倍的还原。结论:考虑含脂质体的伏立康唑制剂的益处,例如纯药物的副作用减少以及最小化药物毒性与增强的药物生物利用度和稳定性相结合,可用于药物敏感和耐药物种。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号